PIK3CD and prostate carcinoma: This was observed in a panel of breast, melanoma, lung, colon, prostate cancer cells treated in vitro with the PI3K inhibitors WAY-175 and WAY-176 (Yu et al., 2008), in a panel of human lung, colon, breast, pancreatic, ovarian, and multiple myeloma cell line derived xenografts treated with the PI3K inhibitor PX866 (Ihle et al., 2009), and in cell line panels of various tumor types treated in vitro with the allosteric mTOR inhibitors Everolimus (Di Nicolantonio et al., 2010) or Rapamycin (Meric-Bernstam et al., 2012).